HalioDx closed a Series B round of €18.5 million (US$22.3 million)

| January 17, 2018
  • This funding will accelerate the development of Immunoscore® in selected cancers, and support set up of commercial activities in the US
  • This round was led by PSIM fund managed by Bpifrance in the framework of the program ‘Investing for the Future’

haliodxlogoMarseille, France, January 17, 2018 – HalioDx, a diagnostic company expert in the analysis of the tumor microenvironment, announces today the closing of a 18.5 million euros Series B financing after a Series A round of 8 M€ in March 2015. The new investment funds are PSIM fund managed by Bpifrance in the framework of the program ‘Investing for the Future’, Quest for Growth managed by Capricorn venture Partners and Amundi Private Equity Funds, joined by the company’s historical investors: MI Care S.A., Sham Innovation Santé/Turenne, BNP Paribas Development and Sofipaca.

This fundraising is intended to accelerate the development of Immunoscore® for colon cancer and selected additional cancer types and set up commercial activities in the US. Immunoscore® is a breakthrough diagnostic platform based on the analysis of the tumor microenvironment combining immunohistochemistry and advanced digital pathology to guide oncologists in optimizing the management of their patients. In colon cancer, the company has already accumulated a strong body of clinical evidence in predicting individual risk of recurrence and is progressing toward reimbursement decisions for Immunoscore® in several countries.

In parallel, the company developed a significant immune biomarker partnering program with Biopharma to assess the predictive value of Immunoscore® and other proprietary assays, notably Immunosign® and Halioseek®. These studies are conducted in the context of various therapeutic modalities and in multiple indications, including companion diagnostics approaches for specific immunotherapies.

“We are conducting an ambitious plan to develop our unique portfolio of diagnostic solutions to contribute to precision medicine. In the past 2 years, HalioDx has been delivering data and diagnostic solutions beyond its own plans. This Series B financing will enable us to execute our plans faster & enter efficiently the US market. I am looking forward to see Immunoscore® development in oncologists’ routine practice to manage prescriptions across multiple cancer indications” comments Vincent Fert, CEO of HalioDx.

Olivier Martinez, Senior Investment Director, Life Sciences, Bpifrance, adds: “We are delighted to support HalioDx at a crucial time for the company by mobilizing our PSIM fund reserved for winners of the World Wide Innovation Challenge. Based on the clinical results already achieved with Immunoscore®, the perspectives for other diagnostic solutions under development, and the strong experience and ambition of its management team, we are convinced that HalioDx has the potential to become a leading company in the field of precision medicine applied to cancer immunotherapy.”


About HalioDx
The Immune Response to Cancer Diagnostics
HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Immunoscore® proprietary technology, pioneered by Dr Jérôme GALON at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a diagnostic solution for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications. HalioDx also develops assays such as Halioseek® and Immunosign® to help stratifying patients for immunotherapies.

HalioDx has an experienced team of more than 130 employees, a CLIA laboratory and compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. Based in Marseille, France, the company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites www.haliodx.com, www.immunoscore-colon.com and www.halioseek.com and follow the company on Twitter @HalioDx.

Source: HalioDx


Tags: , , , , , , , , ,

Category: Clinical Laboratories, Data Management, Device Manufacturers, Digital Pathology News, File format, Image Analysis, Laboratory Informatics, New Digital Imaging Technologies, Pathology News, Vendor products

Comments are closed.